On the 5th of January 2011, Capricorn Venture Partners announced that its Capricorn Health-tech Fund raised €42 million in a first closing.
The Capricorn Health-Tech Fund (CHF) will be focusing on early to mid-stage human health-technology companies in Europe. CHF defines health-technology as any technology based product used for the prevention, the diagnosis or the treatment of diseases and medical indications in humans. This includes the following subsectors: biopharmaceutical and pharmaceutical drugs, vaccines, medical devices, medical imaging, diagnostics, (research) equipment, nutraceuticals and functional foods.
This and other specialized funds such as LRM's life sciences fund can provide the necessary financial means to help fuel the development of the life sciences sector in Flanders!